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Tuberculosis infection risk, preventive
therapy care cascade and incidence of
tuberculosis disease in healthcare workers
at Maputo Central Hospital
Susannah K. Graves1* , Orvalho Augusto2, Sofia Omar Viegas3, Philip Lederer4, Catarina David5, Kristen Lee4,
Anila Hassane5, Anilsa Cossa5, Salma Amade5, Susete Peleve5, Pereira Zindoga5, Leguesse Massawo3,
Francesca J. Torriani1,6* and Elizabete A. Nunes5*
Abstract
Background: Mozambican healthcare workers have high rates of latent and active tuberculosis, but occupational
screening for tuberculosis is not routine in this setting. Furthermore, the specificity of tuberculin skin testing in this
population compared with interferon gamma release assay testing has not been established.
Methods: This study was conducted among healthcare workers at Maputo Central Hospital, a public teaching
quaternary care hospital in Mozambique. With a cross sectional study design, risk factors for tuberculosis were
assessed using multivariable logistic regression. The care cascade is reported for participants who were prescribed
six months of isoniazid preventive therapy for HIV or highly reactive testing for latent tuberculosis infection. The
agreement of interferon-gamma release assay results with positive tuberculin skin testing was calculated.
Results: Of 690 screened healthcare workers, three (0.4%) had active tuberculosis and 426 (61.7%) had latent
tuberculosis infection. Less education, age 35–49, longer hospital service, and work in the surgery department were
associated with increased likelihood of being tuberculosis infected at baseline (p < 0.05). Sex, Bacillus Calmette-
Guerin vaccination, HIV, outside tuberculosis contacts, and professional category were not. Three new cases of
active tuberculosis developed during the follow-up period, two while on preventive therapy. Among 333
participants offered isoniazid preventive therapy, five stopped due to gastrointestinal side effects and 181
completed treatment. For HIV seropositive individuals, the agreement of interferon gamma release assay positivity
with positive tuberculin skin testing was 50% among those with a quantitative skin test result of 5-10 mm, and
among those with a skin test result ≥10 mm it was 87.5%. For HIV seronegative individuals, the agreement of
interferon gamma release assay positivity with a tuberculin skin test result of 10-14 mm was 63.6%, and for those
with a quantitative skin test result ≥15 mm it was 82.2%.
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Conclusions: There is a high prevalence of tuberculosis infected healthcare workers at Maputo Central Hospital.
The surgery department was most heavily affected, suggesting occupational risk. Isoniazid preventive therapy
initiation was high and just over half completed therapy. An interferon gamma release assay was useful to discern
LTBI from false positives among those with lower quantitative tuberculin skin test results.
Keywords: Tuberculosis, Latent tuberculosis infection, Interferon-gamma release assay, Healthcare workers, HIV,
Isoniazid preventive therapy
Background
Tuberculosis disease (TB), with its high morbidity and
mortality, depletes human resources in high burden
countries [1, 2]. Mozambique has a high TB burden,
with 159,000 active cases in 2016. HIV is highly preva-
lent, affecting 45% of Mozambicans with TB [3].
Worldwide, healthcare workers (HCW) in low and
middle income countries have high rates of latent TB in-
fection (LTBI) [4, 5] and recent reviews have made the
case for focusing on infection control practices in these
settings including routine screening and reporting of TB
among workers at health facilities [4, 6].
Mozambican HCW have high rates of active TB
and LTBI. A recent study among 209 HCW in Nam-
pula, Mozambique showed an LTBI rate of 34.4% [7]
and another among 505 HCW in nearby South Africa
demonstrated rates of 62–84% [8]. Although
Mozambique adapted its tuberculosis infection pre-
vention and control guidelines to comply with the
World Health Organization’s (WHO) 2009 policy [9],
these measures are inconsistently implemented in
Mozambican health facilities [10]. At Maputo Central
Hospital (MCH), occupational TB has been a signifi-
cant challenge, prompting implementation of tubercu-
losis infection prevention and control measures,
including forming the Nucleus of Tuberculosis Con-
trol in 2011 with a mandate to screen and treat
workers for TB and LTBI.
Throughout the world, identification of HCWs who
may benefit from chemoprophylaxis with isoniazid pre-
ventive therapy (IPT) has historically been performed
using the tuberculin skin test (TST). More recently,
interferon-gamma release assays (IGRAs) are being
implemented. Few prior studies in sub-Saharan Afri-
can HCWs have used IGRA responses to evaluate the
burden of LTBI. While occupational risk factors asso-
ciated with LTBI have been identified [4, 5, 11–14],
there has only been one study to date in Mozambican
HCW [7].
This study aimed to establish the burden of active TB
disease among HCWs at MCH and identify those at
highest risk of being TB infected. It further assessed the
care cascade of IPT in this setting, as well as agreement
of IGRA with positive TST results.
Methods
Study design and setting
This is a cross sectional screen for active TB and LTBI
with 6 months of follow-up to assess TB incidence and
IPT care cascade. MCH is the largest hospital in
Mozambique, with 1400 beds and 3679 HCW in 2013.
Conditions are crowded and the facility is poorly venti-
lated. By policy, masks are available to staff and cough-
ing patients but use is neither mandated nor consistent.
There is no facility for the isolation of admitted TB sus-
pects. Radiology, pathology and sputum microscopy are
available on-site.
Study population and recruitment
In 2013, all 3679 workers at least 18 years old, working
at MCH for at least two years were invited to participate.
Participants were recruited through posted flyers and in-
formational sessions. Exclusion criteria were as follows:
immune-suppressive therapy with steroids for over four
weeks, recent live vaccine, prior active TB, or history of
ulceration with TST. Of the 777 healthcare workers who
responded, 758 were eligible and provided informed
consent. Additional informed consent was obtained for
those agreeing to HIV testing.
Demographics and risk assessment
Demographics and tuberculosis exposure history were
collected via interviews in Portuguese by study physi-
cians at enrollment. Age, sex, education level, length of
hospital service, department, professional category, Ba-
cillus Calmette-Guerin (BCG) vaccination status and ex-
posure to close contacts with active TB were solicited
from each participant.
Active TB screening
Symptoms of cough greater than two weeks, productive
cough, hemoptysis, chest pain, fever, sweats, weight loss or
weakness were solicited. All participants, with the exclusion
of pregnant women, underwent a chest X-ray which was
interpreted by a study radiologist or pulmonologist who
was blinded to the symptom questionnaire. Those with any
symptoms or suspicious X-ray findings underwent further
testing, including sputum collection. Sputum samples were
analyzed with fluorescence microscopy using Auramine O
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staining procedure, and nucleic acid amplification testing
(GeneXpert, Cepheid) followed by mycobacterial culture in
liquid media (BBL™ MGIT™, Becton, Dickinson and Com-
pany) and solid Löwenstein-Jensen media slants (BBL™
Lowenstein-Jensen Medium, Becton, Dickinson and Com-
pany). Further workup of computed tomography, bron-
choscopy, and/or fine-needle aspiration were performed as
indicated by a study pulmonologist.
Active TB cases were defined as positive laboratory
testing (smear, culture, or nucleic acid amplification test)
in a patient with suggestive symptoms and/or imaging.
Laboratory testing for HIV and LTBI
All workers agreeing to HIV testing underwent HIV 1/2
immunochromatographic lateral flow antibody testing
(Determine™ HIV-1/2 test, Abbott Laboratories). Initially
reactive samples underwent confirmatory testing with an
immunochromatographic assay (UniGold™ HIV-1/2 test,
Trinity Biotech) according to the Mozambican national
HIV testing algorithm. Those with confirmed HIV
underwent CD4 T-cell count.
Participants in whom active TB was ruled out under-
went testing for LTBI using a two-step process. First, a
quantitative TST was performed. For those with a TST
induration of at least 10 mm (if HIV-) or at least 5 mm
(if HIV+), an IGRA (QuantiFERON®-TB Gold, Cellestis)
was performed when they returned for TST reading at
72 h.
Latent tuberculosis classification
LTBI classifications are outlined in Table 1. HIV sero-
negative participants with TST induration of 10–14mm
or quantitative IGRA 0.35–0.99 IU/mL were designated
as LTBI “low reactors” along with HIV seropositive par-
ticipants with TST of 1-4 mm. HIV seropositive partici-
pants with TST induration of at least 5 mm, and those
with a negative HIV antibody test and a TST of at least
15 mm together with an IGRA result of at least 1.0 were
designated LTBI “high reactors.” Those who declined
HIV testing but had TST induration of ≥1 mm were
classified as LTBI “undetermined reactor status.”
IPT treatment assignment
After excluding active TB disease, all participants newly
diagnosed with HIV were prescribed isoniazid 300mg
daily for six months according to contemporary Mozam-
bican infection control and HIV/TB treatment guidelines
[9, 15]. Additionally, those designated as “high reactor”
LTBI were offered IPT.
Statistical analysis
The agreement of IGRA positivity with positive TST re-
sults was reported for the baseline screening, stratified
by quantitative TST response. Frequencies of participant
characteristics were reported at baseline as well as follow
up. LTBI at baseline (defined above) was compared for
the following risk factors: sex, age category, education
level, duration of hospital service (five-year increments),
work type, department, exposure to close contacts with
TB outside of work, and HIV status. For dichotomous
variables, chi-squared analysis was used. For variables
with more than two categories univariate logistic regres-
sion with Wald chi-squared test statistic to evaluate for
overall significance was used. Unadjusted odds ratio
(OR), 95% confidence interval (CI) and p-value were re-
ported. To compare the adjusted odds of LTBI in various
Table 1 Latent tuberculosis classification
HIV serostatus TST induration TST qualitative IGRA IU/mL LTBI Class
Negative HIV Ab
Negative 0-9 mm Negative n/a No LTBI
Negative 10-14 mm Positive Any Low reactor
Negative ≥15mm Positive 0.35–0.99 Low reactor
Negative ≥15mm Positive ≥1.00 High reactor
Positive HIV Ab
Positive 0 Negative n/a No LTBI
Positive 1-4 mm Positive Any Low reactor
Positive ≥5 mm Positive Any High reactor
Unknown HIV Ab
Unknown 0 Negative n/a No LTBI
Unknown 1-9 mm Uninterpretable Any Undetermined
Unknown 10-14 mm Positive Any Undetermined
Unknown ≥15mm Positive 0.35–0.99 Undetermined
Unknown ≥15mm Positive ≥1.00 High reactor
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departments, a multivariable logistic regression model
was generated using department as the main effect and
adjusting for covariates that were found to have p < 0.2
in the univariate analysis: age category, education, dur-
ation of service, and exposure to TB contacts outside of
work. Significant interactions between age category and
duration of hospital service as well as age group and de-
partment were identified, so a model stratified by age
group was also generated (See Additional file 1). ORs
and 95% CIs for the main effect as well as two-tailed
p-values were reported. Given that loss-to-follow-up at
6 months was nearly 50%, baseline characteristics of
those who did and did not follow up were compared
using a chi-squared test statistic. Active tuberculosis in-
cidence was calculated using the denominator of all
who followed up multiplied by the duration of
follow-up (6 months). All testing for significance was
done using two-tailed alpha-level 0.05. Hosmer-Leme-
show goodness-of-fit testing was performed and toler-
ances calculated for the model to assess for collinearity.
Outliers identified by Pearson Residuals were investi-
gated. Statistical analysis was performed using SAS®
Studio statistical software, version 3.6.
Results
Population characteristics
Of 777 workers screened for participation, 758 met cri-
teria for enrollment in the study, and 690 completed the
screening process which included a symptom question-
naire, chest X-ray, and testing for tuberculosis and HIV
(Fig. 1).
Baseline characteristics are summarized in Table 2.
Women comprised 74.2% of participants. Represented
professional categories included auxiliary personnel
(49.0%), nurses (17.7%), administrative personnel
(14.8%), doctors (6.8%), laboratory (4.1%) and other
(7.7%) staff. Of the 645 participants who underwent HIV
testing, 78 (12.1%) tested positive, representing 11.3% of
the whole sample.
Tuberculosis diagnosis
Diagnosis of tuberculosis and LTBI at baseline screening
is summarized in Table 2. Three cases of active TB were
diagnosed at screening (0.4%) as well as 426 (61.8%) in-
dividuals with LTBI, 285 of whom were high reactors
(41.3% of total participants). The remaining 261 (37.8%)
participants were classified as “no LTBI.” Three add-
itional active TB cases were diagnosed during follow up.
The six active TB cases, described in Table 3, were from
five different departments.
Univariate analysis
The univariate analysis comparing odds of LTBI is
shown in Table 4. Age was significantly associated with
LTBI, with those 35 to 49 years of age more likely to be
positive for LTBI compared with those less than 35
years, OR 1.66 (95% CI 1.16, 2.37). Secondary or higher
education was associated with lower odds of LTBI com-
pared with the reference group of primary education or
less, ORs of 0.63 (95%CI 0.43, 0.93) and 0.57 (95%CI
0.35, 0.94) respectively. The odds of LTBI increased with
service duration with OR 1.12 (95% CI 1.04, 1.21) for
each additional 5 years of service. Odds of LTBI were
higher in the surgery department with OR 2.43 (95% CI
1.31, 4.49) and were lower in the medicine department
with OR 0.53 (95% CI 0.30, 0.92) compared with
non-clinical departments. Odds of LTBI did not vary by
68 with no questionnaire or 
initial TST not read.
777 registered
758 included
19 excluded
690 completed TST, CXR 
and questionnaire 
261 without LTBI 426 with LTBI 3 active TB cases
LTBI classification,
IPT offered to 333
Fig. 1 Study participation flow diagram
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sex, professional category, BCG vaccination status, out-
side TB contacts or HIV status.
Multivariable logistic regression analysis
Summary statistics for the multivariable logistic regres-
sion model adjusted for age, education level, TB contact
outside of work, service duration and department are
shown in Table 5. Longer duration of hospital service
was associated with increased odds of LTBI with OR
1.17 (95%CI 1.04, 1.31) for 5-year intervals, as was work
in the surgery department with OR 2.31 (95%CI 1.27,
4.44). Age over 50 years was associated with reduced
odds of LTBI with OR 0.48 (95% CI 0.26, 0.89), as was
work in the medicine department with OR 0.56 (95%CI
0.31, 0.98). A multivariable logistic regression model
stratified by age group is described in the supplement
[see Additional file 1].
Six-month follow up
Of the 687 participants without active TB disease who
completed initial screening, 358 (52.1%) reported for re-
peat evaluation at the six-month follow up interval. Ac-
tive TB incidence among those who reported for
evaluation at six months was three in 179 person-years,
or 1676/100,000 person-years (95% CI 350, 4820). A
summary comparing baseline characteristics of those
Table 2 Baseline characteristics of study participants
Baseline Characteristic N (%) Total = 690
Sex
Male 178 (25.8)
Female 512 (74.2)
Age (years)
Less than 35 227 (32.9)
35–49 303 (43.9)
50 or more 160 (23.2)
Education Level
Primary or less 169 (24.5)
Secondary 405 (58.7)
College/University 116 (16.8)
Known outside TB contact
No TB contact 565 (81.9)
TB contact 125 (18.1)
BCG scar
Absent 54 (7.8)
Present 606 (87.8)
Unsure/missing 30 (4.3)
HIV status
HIV+ 78 (11.3)
HIV- 567 (82.2)
Missing/declined testing 45 (6.5)
Professional category
Administrative 102 (14.8)
Physician 47 (6.8)
Nurse 122 (17.7)
Laboratory Technician 28 (4.1)
Auxiliary Staff 338 (49.0)
Other 53 (7.7)
Department
All Non-Clinical 97 (14.1)
Medicine 110 (15.9)
Obstetrics and Gynecology 111 (16.1)
Pediatrics 85 (12.3)
Surgery 107 (15.5)
Clinical Labs and Pathology 61 (8.8)
Emergency and Critical Care 33 (4.8)
Other Clinical Departments 86 (12.5)
Length of Service (years)
Less than 20 453 (65.7)
20 or more years 237 (34.4)
Baseline Tuberculosis Status
No LTBI 261 (37.8)
LTBI, low reactor 127 (18.4)
LTBI, high reactor 285 (41.3)
LTBI, undetermined reactor 14 (2.0)
Active TB 3 (0.4)
Table 3 Clinical Characteristics of active TB cases
Characteristic Evaluated in n
(Total n = 6)
Positive (abnormal)
finding
Clinical Type
Pulmonary 6 4
Lymphadenitis 6 1
Pulmonary +
Lymphadenitis
6 1
Baseline Screening
Symptom Screen 6 1
Chest Xray 6 4
TST 6 4
IGRA 5 4
Mycobacterial Lab Studies
Acid Fast Stain (sputum
or FNA)
3a 3
Mycobacterial culture
(sputum)
1b 1
Nucleic Acid Amplification
(sputum)
5 4
aSputum was obtained from the other 3 individuals including induced
specimens from 2 individuals, but these were inadequate for
evaluation (saliva)
bAn additional sputum culture was performed but results could not be
interpreted due to contamination
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who followed up compared with those who did not is
shown in Table 6. Participants who followed up did not
differ from those who did not follow up with respect to
education level, outside TB contacts, HIV status and
professional category. However, males, younger partici-
pants, those who worked less than 20 years, and those
without LTBI at baseline were less likely to report for
follow up.
IPT care cascade
A flow diagram of the care cascade for the 333 partici-
pants offered IPT is shown in Fig. 2. Of 333 participants
offered IPT, 234 initiated and 99 declined. Of initiators,
181 completed six months, five stopped due to gastro-
intestinal side effects, and 46 abandoned treatment. Two
cases of drug-sensitive extrapulmonary TB developed
during follow-up in participants receiving IPT. One case
of active pulmonary TB developed in a participant who
declined IPT.
Operating characteristics of TST and IGRA
The agreement of positive IGRA with positive TST,
stratified by quantitative TST response, is shown in
Table 7. For HIV seropositive individuals, the agreement
of positive IGRAs with positive TST results was 50%
among those with TST 5-10 mm, and 87.5% among
those with TST ≥ 10mm. For HIV seronegative individ-
uals, the agreement of TST 10-14 mm with positive
IGRA results was 63.6%, and for TST ≥ 15 mm it was
82.2%.
Table 4 Univariate analysis with unadjusted odds ratio of LTBI
for specified baseline characteristics
Characteristic OR (95% CI) p-value
Sex 0.530
Male ref
Female 1.13 (0.79, 1.60)
Age (years) 0.016
Less than 35 ref
35–49 1.66 (1.16, 2.37)
50 or more 1.15 (0.76, 1.73)
Education Level 0.038
Primary or less ref
Secondary 0.63 (0.43, 0.93)
College/University 0.57 (0.35, 0.94)
BCG scar 0.379
Absent ref
Present 0.75 (0.41, 1.36)
Known outside TB contact 0.125
No TB contact ref
TB contact 0.72 (0.49, 1.07)
HIV status 1.000
HIV- ref
HIV+ 1.00 (0.61, 1.64)
Professional category 0.500
Administrative ref
Physician 0.62 (0.31, 1.24)
Nurse 1.03 (0.60, 1.77)
Laboratory Technician 1.36 (0.56, 3.31)
Auxiliary Staff 1.15 (0.73, 1.81)
Other 1.03 (0.52, 2.05)
Department < 0.001
All Non-Clinical ref
Obstetrics and Gynecology 1.15 (0.66, 2.01)
Pediatrics 1.06 (0.58, 1.92)
Surgery 2.43 (1.31, 4.49)
Medicine 0.53 (0.30, 0.92)
Clinical Labs and Pathology 1.45 (0.74, 2.86)
Emergency and Critical Care 1.79 (0.75, 4.27)
Other Clinical 0.93 (0.52, 1.69)
Length of Service (5 year increase) 1.12 (1.04, 1.21) 0.002
Table 5 Odds of LTBI adjusted for age, education, outside TB
contact, length of service and department
Characteristic OR (95% CI) p-value
Age (years) 0.002
less than 35 ref
35–49 1.15 (0.76, 1.75)
50 or more 0.48 (0.26, 0.89)
Education Level 0.139
Primary or less ref
Secondary 0.64 (0.41, 0.99)
College/University 0.70 (0.38, 1.27)
Known outside TB contact 0.313
No TB contact ref
TB contact 0.80 (0.53, 1.23)
Length of Service (5 year increase) 1.17 (1.04, 1.31) 0.007
Department 0.001
All Non-Clinical ref
Obstetrics and Gynecology 1.07 (0.59, 1.91)
Pediatrics 1.02 (0.55, 1.89)
Surgery 2.37 (1.27, 4.44)
Medicine 0.56 (0.31, 0.98)
Clinical Labs and Pathology 1.57 (0.78, 3.16)
Emergency and Critical Care 1.82 (0.75, 4.43)
Other Clinical 0.95 (0.52, 1.74)
Hosmer-Lemeshow goodness-of-fit test p-value = 0.337
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Discussion
Mozambique is among the countries with the highest
burden of HIV and TB in the world. At the time of this
study in 2013 the national prevalence of HIV was 11.5%.
The national incidence of TB was 552/100,000 persons
in Mozambique in 2013 [16]. Health workers are at es-
pecially risk of TB due both to frequent exposure to pa-
tients with infectious TB and because they may also be
immunocompromised due to HIV.
In this study we observed 6 cases of tuberculosis, 3
of which were diagnosed during follow-up. The
resulting calculated annual incidence of 1676/100,000
persons shows a trend toward higher active TB inci-
dence than the background annual incidence. The in-
cidence of active TB among HCW at MCH is
comparable to the median incidence of 1180/100,000
reported in a meta-analysis of active TB in HCW
from high-incidence countries [17]. Similarly, in a
study conducted in Tete, Mozambique in 2010, 21%
of HCW reported prior TB disease with 2.1% diag-
nosed with active TB disease at screening or during
follow up (incidence not specified) [18]. Therefore,
our findings support previous work suggesting occu-
pational risk plays a major role in this setting.
One of the limitations of our study is that nearly half
of participants did not follow up, including a signifi-
cantly higher proportion of those without LTBI at base-
line. This may have resulted in an overestimation of the
incidence of active TB disease.
Much of TB transmission in MCH is likely from un-
suspected cases, particularly on services where the chief
complaint may be unrelated to TB. In a review of 653
autopsies at MCH, 69 cases of tuberculosis were diag-
nosed that were unrecognized prior to autopsy, and 44
of these were pulmonary cases [19]. The “Find Actively,
Separate and Treat” (FAST) protocol [20] was imple-
mented: patient symptom assessments are done at
check-in, with masks and priority given to coughing pa-
tients, combined with point-of-care sputum microscopy
and nucleic acid amplification testing for TB. Addition-
ally, upper-room germicidal ultraviolet units were in-
stalled [21] to address this problem. Of note, the odds of
LTBI for HCW in the medicine department were signifi-
cantly lower, possibly due to infection prevention initia-
tives focusing on this department.
We note that participants aged 35–49 showed the
highest rate of LTBI while those in the oldest age group
showed lower rates. This may partly reflect the waning
interferon-gamma response in older individuals [22] ra-
ther than a true lower rate in this group. In the un-
adjusted analysis, workers with longer service duration
were more likely to have LTBI.
In the present study, uptake among HCWs at MCH
was only 70%, with 54% completing treatment even
Table 6 Comparison of baseline characteristics between those
who did and did not follow up
Baseline Characteristic No Follow-up
N (%)
Total = 329
Follow-up
N (%)
Total = 358
p-value
Sex < 0.001
Male 106 (32.2) 71 (19.8)
Female 223 (67.8) 287 (80.2)
Age (years) 0.001
Less than 35 129 (39.2) 96 (26.8)
35–49 137 (41.6) 165 (46.1)
50 or more 63 (19.1) 97 (27.1)
Education Level 0.037
Primary or less 69 (21.0) 99 (27.7)
Secondary 195 (59.3) 209 (58.4)
College/University 65 (19.8) 50 (14.0)
Known outside TB contact 0.636
No TB contact 272 (82.7) 291 (81.3)
TB contact 57 (17.3) 67 (18.7)
HIV status 0.243
HIV+ 36 (10.9) 40 (11.2)
HIV- 266 (80.9) 300 (83.8)
Missing/declined 27 (8.2) 18 (5.0)
Length of Service (years) < 0.001
Less than 20 239 (72.6) 211 (58.9)
20 or more years 90 (27.4) 147 (41.0)
Professional category 0.300
Administrative 49 (14.9) 53 (14.7)
Physician 28 (8.5) 19 (5.3)
Nurse 61 (18.5) 61 (17.0)
Laboratory Technician 16 (4.9) 12 (3.4)
Auxiliary Staff 148 (45.0) 188 (52.5)
Other 27 (8.2) 25 (7.0)
Department < 0.001
All Non-Clinical 38 (11.6) 59 (16.5)
Obstetrics and Gynecology 32 (9.7) 79 (22.1)
Pediatrics 56 (17.0) 29 (8.1)
Surgery 48 (14.6) 58 (16.2)
Medicine 54 (16.4) 55 (15.4)
Clinical Labs and Pathology 35 (10.6) 25 (7.0)
Emergency and Critical Care 15 (4.6) 18 (5.0)
Other Clinical 51 (15.5) 35 (9.8)
Baseline Tuberculosis Status < 0.001
No LTBI 156 (47.4) 105 (29.3)
LTBI, low reactor 58 (17.6) 69 (19.3)
LTBI, high reactor 106 (32.2) 179 (50.0)
LTBI, undetermined reactor 9 (2.7) 5 (1.4)
Active TB excluded excluded
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though IPT for LTBI reduces the risk of active TB [23]
and is recommended by WHO for newly diagnosed
HIV+ individuals in high-TB-burden countries [24].
This care cascade is similar to findings in a recent
meta-analysis in which 84.4% of HCW initiated and
50.4% completed therapy [25]. However, it compares
favorably with completion rates in low- and middle-in-
come countries in the same study (16.7%) as well as
those in a recent study in nearby Swaziland [26]. Newer
short-course regimens improve completion and have
shown promise in similar high-incidence popula-
tions [27–30].
Two participants developed extrapulmonary disease
while on IPT, suggesting that these manifestations may
be easily missed with symptom screening and chest
Xray. While there were no serious adverse events, five
participants discontinued therapy due to side effects.
Because the protection from active disease conferred
by mass IPT is transient in congregate settings with high
reinfection risk [31], studies are needed to further define
the role of targeted IPT in high burden settings with on-
going exposure to infectious TB.
Lastly, in contrast to a recent study of HCW in South
Africa which demonstrated poor agreement between
TST and IGRA [32], a high TST response (≥15mm in
HIV- or ≥ 10mm in HIV+) had over 80% agreement
with IGRA positivity in the present study. This affirms
that TST remains a valid test in this resource-limited
setting. Conversely, there was poor agreement between
low positive TST results and positive IGRA results. Al-
though nontuberculous mycobacteria can cause positive
TST results, these infections are much less common
than TB among persons living with HIV in Mozambique
[33].This suggests that IGRAs could be helpful to dis-
cern LTBI from false positive TST among those with low
positive TST results in this highly BCG vaccinated
population.
Conclusions
HCW at MCH face high rates of both active TB and
LTBI with the highest rates of LTBI in the surgery de-
partment. In the study population, TST is useful for
diagnosing LTBI for those with higher quantitative re-
sponses, and IGRA is useful to discern LTBI from false
positives among those with lower quantitative TST. IPT
acceptance was high, but achieving high completion
rates remains a challenge. New short-course preventive
therapy regimens seem promising in this regard. Fur-
thermore, two cases of active extrapulmonary TB devel-
oped in individuals on IPT. Future interventions to
decrease occupational TB through preventive therapy
should focus on better routine screening algorithms to
identify both pulmonary and extrapulmonary TB. This is
particularly important in populations with high HIV
prevalence.
333 offered IPT
234 initiated IPT
181 completed 
six months IPT
2 cases of active TB 
(extrapulmonary)
51 incomplete 
therapy
5 stopped due to gastro-
intestinal side effects
46 abandoned 
treatment
99 declined IPT
1 active TB case
Fig. 2 Care cascade of participants who were offered IPT
Table 7 Agreement of IGRA positivity with TST positive results
HIV+ HIV-
TST result (mm) TST+ n = 28 IGRA + Agreement of IGRA+ with TST+ TST+ n = 308 IGRA + Agreement of IGRA+ with TST+
total 28 23 82.1% 308 243 78.9%
5–9 4 2 50.0% – – –
10–14 8 7 87.5% 55 35 63.6%
≥ 15 16 14 87.5% 253 208 82.2%
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